Polaryx Therapeutics, Inc. (PLYX)
Nasdaq · Healthcare · Biotechnology
$2.07−0.48%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $103M
- 52-week range
- $1.85 – $48.91
- 52-week change
- −94.06%
- EPS (trailing)
- −$0.14
Fiscal year to Dec 2025
- Net income
- −$9.0M
- Diluted EPS
- −$0.20
From the company’s annual report on SEC EDGAR.
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Headquarters: Paramus, United States · 2 employees · polaryx.com